



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

PRODUCT INFORMATION




PF-06873600

Item No. 35502

CAS Registry No.: 2185857-97-8
Formal Name: 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-pyrido[2,3-d]pyrimidin-7(8H)-one

Synonym: PF-3600
MF: C₂₀H₂₇F₂N₅O₄S
FW: 471.5
Purity: ≥98%
UV/Vis.: λ_{max}: 228, 350 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PF-06873600 is supplied as a solid. A stock solution may be made by dissolving the PF-06873600 in the solvent of choice, which should be purged with an inert gas. PF-06873600 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of PF-06873600 in these solvents is approximately 15 and 10 mg/ml, respectively.

Description

PF-06873600 is an inhibitor of cyclin-dependent kinase 2 (Cdk2), Cdk4, and Cdk6 (K_i s = 0.13, 1.25, and 0.11 nM, respectively).¹ It is selective for these CDKs over Cdk1 and Cdk9 (K_i s = 4.5 and 19.6 nM, respectively). PF-06873600 inhibits the phosphorylation of RB transcriptional corepressor 1 (RB1) in, and the proliferation of, OVCAR-3 ovarian cancer cells (EC_{50} s = 19 and 45 nM, respectively). *In vivo*, PF-06873600 (30 mg/kg) reduces tumor volume in CTG-0464 and CTG-01912 non-small cell lung cancer (NSCLC) patient-derived xenograft (PDX) mouse models.

Reference

1. Freeman-Cook, K.D., Hoffman, R.L., Behenna, D.C., *et al.* Discovery of PF-06873600, a CDK2/4/6 inhibitor for the treatment of cancer. *J. Med. Chem.* **64**(13), 9056-9077 (2021).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM